



Prescription Services

Respiratory National Charts

Supporting the NHS, supplying the NHS, protecting the NHS

NHS Prescription Services is a service provided by the NHS Business Services Authority


Prescription Services

1	Respiratory System	21	Prescribing of Seretide inhaler by strength
2	Respiratory System - Index of national charts	22	Spending on Seretide inhaler by strength
3	Spending on Selective Beta Agonists	23	Prescribing of Leukotriene Receptor Antagonists
4	Usage of Selective Beta Agonists	24	Spending on Leukotriene Receptor Antagonists
5	Spending on Long-acting Selective Beta Agonists	25	Prescribing of Non-sedating Antihistamines
6	Usage of Long-acting Selective Beta Agonists	26	Spending on Non-sedating Antihistamines
7	Spending on Selective Beta Agonists (by device)	27	Prescribing of Sedating Antihistamines
8	Usage of Selective Beta Agonists (by device)	28	Spending on Sedating Antihistamines
9	Prescribing of Selective Beta Agonists (syrups)	29	Prescribing of Mucolytics
10	Spending on Selective Beta Agonists (syrups)	30	Spending on Mucolytics
11	Prescribing of Selective Beta Agonists (tablets/capsules)	31	Prescribing of and Spending on NRT
12	Spending on Selective Beta Agonists (tablets/capsules)	32	Prescribing of NRT by formulation
13	Spending on Antimuscarinic Bronchodilators (including combinations)	33	Spending on NRT by formulation
14	Usage of Antimuscarinic Bronchodilators (including combinations)	34	Prescribing of and Spending on Bupropion
15	Spending on Inhaled Corticosteroids (excluding combinations)	35	Prescribing of and Spending on Varenicline
16	Usage of Inhaled Corticosteroids (excluding combinations)	36	Prescribing of NICE Drugs for Influenza (incl. Amantadine)
17	Spending on Inhaled Corticosteroids (by device)	37	Spending on NICE Drugs for Influenza (incl. Amantadine)
18	Usage of Inhaled Corticosteroids (by device)	38	Prescribing of Prednisolone (tablets v E/C tablets)
19	Spending on Seretide, Symbicort and Fostair	39	Spending on Prednisolone (tablets v E/C tablets)
20	Usage of Seretide, Symbicort and Fostair		

Trends in Spending on Selective Beta₂ Agonists in General Practice in England




Prescription Services



Trends in Usage of Selective Beta₂ Agonists in General Practice in England



Prescription Services




N.B. If no ADQ is available, the DDD has been used instead

Trends in Spending on Long-acting Selective Beta₂ Agonists in General Practice in England




Prescription Services



Trends in Usage of Long-acting Selective Beta₂ Agonists in General Practice in England




Prescription Services



Trends in Spending on Selective Beta₂ Agonists (by Device) in General Practice in England




Prescription Services



Trends in Usage of Selective Beta₂ Agonists (by Device) in General Practice in England



Prescription Services




NB. If no ADQ is available, the DDD has been used instead

Trends in Prescribing of Selective Beta₂ Agonists (Syrup) in General Practice in England




Prescription Services



Trends in Spending on Selective Beta₂ Agonists (Syrup) in General Practice in England




Prescription Services



Trends in Prescribing of Selective Beta₂ Agonists (Tablets/Capsules) in General Practice in England




Prescription Services



Trends in Spending on Selective Beta₂ Agonists (Tablets/Capsules) in General Practice in England




Prescription Services



Trends in Spending on Antimuscarinic Bronchodilators Including Combinations in General Practice in England




Prescription Services



Trends in Usage of Antimuscarinic Bronchodilators Including Combinations in General Practice in England




Prescription Services



Trends in Spending on Inhaled Corticosteroids (excluding Combinations) in General Practice in England




Prescription Services



Trends in Usage of Inhaled Corticosteroids (excluding Combinations) in General Practice in England



Prescription Services




N.B. If no ADQ is available, the DDD has been used instead

For the quarter to September 09, due to the way Budesonide inhaler 200mcg (200 dose) was held on the PPD internal systems, inflated ADQ usage was calculated. Therefore to avoid displaying distorted ADQ figures for Budesonide an average of the quarter to June 09 and December 09 has been utilised.

Trends in Spending on Inhaled Corticosteroids (by Device) in General Practice in England




Prescription Services



Trends in Usage of Inhaled Corticosteroids (by Device) in General Practice in England



Prescription Services




N.B. If no ADQ is available, the DDD has been used

For the quarter to September 09, due to the way Budesonide inhaler 200mcg (200 dose) was held on the PPD internal systems, inflated ADQ usage was calculated. Therefore to avoid displaying distorted ADQ figures for Plain MDI an average of the quarter to June 09 and December 09 has been utilised.

Trends in Spending on Seretide®, Symbicort® and Fostair® in General Practice in England




Prescription Services



Trends in Usage of Seretide®, Symbicort® and Fostair® in General Practice in England



Prescription Services




N.B. If no ADQ is available, the DDD has been used instead

Trends in Prescribing of Seretide® Inhaler by Strength in General Practice in England




Prescription Services



Trends in Spending on Seretide® Inhaler by Strength in General Practice in England



Prescription Services




NB. Evohaler = 120 Dose Accuhaler = 60 Dose

Trends in Prescribing of Leukotriene Receptor Antagonists in General Practice in England




Prescription Services



Trends in Spending on Leukotriene Receptor Antagonists in General Practice in England




Prescription Services



Trends in Prescribing of Non-Sedating Antihistamines in General Practice in England




Prescription Services



Trends in Spending on Non-Sedating Antihistamines in General Practice in England




Prescription Services



Trends in Prescribing of Sedating Antihistamines in General Practice in England




Prescription Services



Trends in Spending on Sedating Antihistamines in General Practice in England




Prescription Services



Trends in Prescribing of Mucolytics (excluding Dornase Alfa) in General Practice in England




Prescription Services



Trends in Spending on Mucolytics (excluding Dornase Alfa) in General Practice in England




Prescription Services



Trends in Prescribing of and Spending on Nicotine Replacement Therapy in General Practice in England




Prescription Services



Trends in Prescribing of Nicotine Replacement Therapy by formulation in General Practice in England




Prescription Services



Trends in Spending on Nicotine Replacement Therapy by formulation in General Practice in England




Prescription Services



Trends in Prescribing of and Spending on Bupropion in General Practice in England




Prescription Services



Trends in Prescribing of and Spending on Varenicline in General Practice in England




Prescription Services



Trends in Prescribing of NICE Drugs for Influenza in General Practice in England




Prescription Services



Trends in Spending on NICE Drugs for Influenza in General Practice in England




Prescription Services



Trends in Prescribing of Prednisolone Tablets and E/C Tablets in General Practice in England



Prescription Services



Trends in Spending on Prednisolone Tablets and E/C Tablets in General Practice in England



Prescription Services

